Pfizer starts Omicron-specific COVID-19 vaccine trial
The Hindu
The trial will involve 1,420 people aged 18-55.
Pfizer and its partner BioNTech have begun enrolment for a clinical trial to test the safety and immune response of their Omicron-specific COVID-19 vaccine in adults aged up to 55, the companies said in a statement on January 25.
Pfizer’s CEO Albert Bourla has previously said that the pharmaceutical giant could be ready to file for regulatory approval of the shot by March.
Run 3 Space | Play Space Running Game
Traffic Jam 3D | Online Racing Game
Duck Hunt | Play Old Classic Game
Prada’s ₹1.2 lakh Kolhapuri chappals have sparked outrage in India, raising questions about cultural appropriation, pricing, and artisan recognition
Ashwini Bhat talks about her journey in setting the national record for women in the Backyard Ultra 2025
Mercedes-Benz introduces the latest AMG GT coupés, blending motorsport technology with elegance, setting a new performance standard in India.
LGBTQIA+ creatives share how they are reclaiming their identity in heteronormative spaces, and why there is a need for more conversations
Group Captain Shubhanshu Shukla to connect with UR Rao Satellite Centre in Bengaluru via ham radio from ISS on July 4.